curacle co., ltd.
A clinical-stage biopharma developing drugs for intractable vascular diseases.
365270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7365270008
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 서초구 효령로 23-1, 서울특별시
- Website:
- http://www.curacle.com/eng/main/
Description
Curacle Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs for intractable vascular diseases. The company's core platform technology centers on developing highly effective protectors against endothelial dysfunction, a key factor in various age-related and vascular conditions. Its development pipeline includes novel treatments targeting significant unmet medical needs, with a particular focus on conditions such as Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (wet AMD), diabetes, and stroke. Curacle aims to create differentiated therapies through innovative targets and treatment concepts, including the development of orally administered medications for complex eye diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-19 00:00 |
감사보고서제출
|
Korean | 18.8 KB | ||
| 2024-03-19 00:00 |
사업보고서 (2023.12)
|
Korean | 387.9 KB | ||
| 2024-03-12 00:00 |
주주총회집중일개최사유신고
|
Korean | 4.4 KB | ||
| 2024-03-12 00:00 |
주주총회소집공고
|
Korean | 158.5 KB | ||
| 2024-03-12 00:00 |
주주총회소집결의
|
Korean | 15.9 KB | ||
| 2024-02-13 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 11.4 KB | ||
| 2024-02-05 00:00 |
투자판단관련주요경영사항(임상시험결과) (CU06 당뇨병성 황반부종 미국 임상 2a 상 탑라인 결과)
|
Korean | 13.3 KB | ||
| 2024-02-05 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2024-01-17 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.3 KB | ||
| 2023-12-26 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2023-12-08 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정)(중증도 내지 중증 궤양성 대장염에 대한 CU104 의 제2상 임상시험 계획(IND) 승인)
|
Korean | 11.7 KB | ||
| 2023-11-14 00:00 |
분기보고서 (2023.09)
|
Korean | 734.9 KB | ||
| 2023-08-29 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청)(CU06-1004 국내 1b상 임상시험 계획(IND) 신청)
|
Korean | 8.6 KB | ||
| 2023-08-11 00:00 |
반기보고서 (2023.06)
|
Korean | 781.3 KB | ||
| 2023-07-17 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청)(중증도 내지 중증 궤양성 대장염에 대한 CU104 의 제2상 임상시험계획승인신청(IND))
|
Korean | 8.4 KB |
Automate Your Workflow. Get a real-time feed of all curacle co., ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for curacle co., ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for curacle co., ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
